Читать книгу - "Живи долго! Научный подход к долгой молодости и здоровью - Майкл Грегер"

from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://pubmed.ncbi.nlm.nih.gov/21067804/

3606

Guber K, Pemmasani G, Malik A, Aronow WS, Yandrapalli S, Frishman WH. Statins and higher diabetes mellitus risk: incidence, proposed mechanisms, and clinical implications. Cardiol Rev. 2021;29(6):314–22. https://pubmed.ncbi.nlm.nih.gov/32947479/

3607

Hong KN, Fuster V, Rosenson RS, Rosendorff C, Bhatt DL. How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD. J Am Coll Cardiol. 2017;70(17):2171–85. https://pubmed.ncbi.nlm.nih.gov/29050566/

3608

Glenn AJ, Li J, Lo K, et al. The Portfolio Diet and incident type 2 diabetes: findings from the Women’s Health Initiative prospective cohort study. Diabetes Care. 2023;46(1):28–37. https://pubmed.ncbi.nlm.nih.gov/36162007/

3609

Sliding scale for LDL: how low should you go? The target for the safest amount of “bad” cholesterol continues to drift downward. Harv Heart Lett. 2011;21(12):5. https://pubmed.ncbi.nlm.nih.gov/21991609/

3610

How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke. Health News. 2004;10(10):6. https://pubmed.ncbi.nlm.nih.gov/15584114/

3611

De Biase SG, Fernandes SFC, Gianini RJ, Duarte JLG. Vegetarian diet and cholesterol and triglycerides levels. Arq Bras Cardiol. 2007;88(1):35–9. https://pubmed.ncbi.nlm.nih.gov/17364116/

3612

Kahleova H, Levin S, Barnard ND. Vegetarian dietary patterns and cardiovascular disease. Prog Cardiovasc Dis. 2018;61(1):54–61. https://pubmed.ncbi.nlm.nih.gov/29800598/

3613

The US Burden of Disease Collaborators, Mokdad AH, Ballestros K, et al. The state of US health, 1990–2016: burden of diseases, injuries, and risk factors among US states. JAMA. 2018;319(14):1444–72. https://pubmed.ncbi.nlm.nih.gov/29634829/

3614

Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension. Curr Hypertens Rep. 2017;19(4):28. https://pubmed.ncbi.nlm.nih.gov/28337713/

3615

Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2003;361(9362):1060]. Lancet. 2002;360(9349):1903–13. https://pubmed.ncbi.nlm.nih.gov/12493255/

3616

Kramer H, Cooper R. Pros and cons of intensive systolic blood pressure lowering. Curr Hypertens Rep. 2018;20(2):16. https://pubmed.ncbi.nlm.nih.gov/29511979/

3617

Kjeldsen SE, Os I, Westheim A. Could adverse events offset the benefit of intensive blood pressure lowering treatment in the Systolic Blood Pressure Intervention Trial? J Hypertens. 2019;37(5):902–4. https://pubmed.ncbi.nlm.nih.gov/30920495/

3618

Fuster V. No such thing as ideal blood pressure: a case for personalized medicine. J Am Coll Cardiol. 2016;67(25):3014–5. https://pubmed.ncbi.nlm.nih.gov/27339499/

3619

Goldhamer A, Lisle D, Parpia B, Anderson SV, Campbell TC. Medically supervised water-only fasting in the treatment of hypertension. J Manipulative Physiol Ther. 2001;24(5):335–9. https://pubmed.ncbi.nlm.nih.gov/11416824/

3620

McDougall J, Litzau K, Haver E, Saunders V, Spiller GA. Rapid reduction of serum cholesterol and blood pressure by a twelve-day, very low fat, strictly vegetarian diet. J Am Coll Nutr. 1995;14(5):491–6. https://pubmed.ncbi.nlm.nih.gov/8522729/

3621

Brown MS, Goldstein JL. Biomedicine. Lowering LDL – not only how low, but how long? Science. 2006;311(5768):1721–3. https://pubmed.ncbi.nlm.nih.gov/16556829/

3622

McGill HC, McMahan CA. Determinants of atherosclerosis in the young. Am J Cardiol. 1998;82(10B):30T-6T. https://pubmed.ncbi.nlm.nih.gov/9860371/

3623

Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281(8):727–35. https://pubmed.ncbi.nlm.nih.gov/10052443/

3624

Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation. 2008;118(6):672–7. https://pubmed.ncbi.nlm.nih.gov/18678783/

3625

Myerburg RJ, Junttila MJ. 2012. Sudden cardiac death caused by coronary heart disease. Circulation. 28;125(8):1043–52. https://pubmed.ncbi.nlm.nih.gov/22371442/

3626

Brown MS, Goldstein JL. Biomedicine. Lowering LDL – not only how low, but how long? Science. 2006;311(5768):1721–3. https://pubmed.ncbi.nlm.nih.gov/16556829/

3627

Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation. 2008;118(6):672–7. https://pubmed.ncbi.nlm.nih.gov/18678783/

3628

Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–5. https://pubmed.ncbi.nlm.nih.gov/15654334/

3629

Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72. https://pubmed.ncbi.nlm.nih.gov/16554528/

3630

Robinson JG, Gidding SS. Curing atherosclerosis should be the next major cardiovascular prevention goal. J Am Coll Cardiol. 2014;63(25):2779–85. https://pubmed.ncbi.nlm.nih.gov/24814489/

3631

Brown MS, Goldstein JL. Biomedicine. Lowering LDL – not only how low, but how long? Science. 2006;311(5768):1721–3. https://pubmed.ncbi.nlm.nih.gov/16556829/

3632

Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol – lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327¿037 participants. Lancet Diabetes Endocrinol. 2020;8(1):36–49. https://pubmed.ncbi.nlm.nih.gov/31862150/

3633

Shapiro MD, Bhatt DL. “Cholesterol-years” for ASCVD risk prediction and treatment. J Am Coll Cardiol. 2020;76(13):1517–20. https://pubmed.ncbi.nlm.nih.gov/32972527/

3634

Kaplan H, Thompson RC, Trumble BC, et al. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. Lancet. 2017;389(10080):1730–9. https://pubmed.ncbi.nlm.nih.gov/28320601/

3635

Penson PE, Pirro M, Banach M. LDL–C: lower is better for longer – even at low risk. BMC Med. 2020;18(1):320. https://pubmed.ncbi.nlm.nih.gov/33032586/

3636

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://pubmed.ncbi.nlm.nih.gov/28444290/